In addition to the day-to-day team, we have assembled the world’s leading experts on transdermal drug delivery, smoking cessation and pharmaceutical commercialization to inform the company’s activities.

With decades of combined experience in research and product development, behavioral science, FDA approval experience, and bringing life-saving products to market, our team possesses a wide-array of knowledge and skills that will help define the next generation of medication delivery.


David Happel
Chief Executive Officer

Tony Rimac
Chief Financial Officer

Patricia Oto, R.Ph.
Senior Vice President of Regulatory Affairs and Quality Assurance

Patrick H. Ruane, Ph.D.
Senior Vice President of Research and Development

Bernie Andreas
Vice President of Engineering

Board of Directors

Aidan King
Co-founder and Managing Partner, Fountain Healthcare

Alan Levy
Former Chief Executive Officer, Chrono Therapeutics

Liz Rockett
Director, Kaiser Permanente Ventures

James W. Young
Venture Partner, 5AM Ventures

David Happel
Chief Executive Officer, Chrono Therapeutics

Wende Hutton
General Partner, Canaan Partners 

Steve James
Chairman and Former Chief Executive Officer, Labrys Biologics, Inc. and KAI Pharmaceuticals, Inc. 

Tim Kilgallon
Chief Executive Officer, Mazlo and Former Chief Executive Officer, Free & Clear, Inc.

Scientific Advisory Board

Richard D. Hurt, M.D.
Founder and Former Director of the Nicotine Dependence Center at the Mayo Clinic

Gary E. Swan, Ph.D.
Consulting Professor Stanford Prevention Research Center at Stanford University School of Medicine


Neal Benowitz, M.D.
UCSF School of Medicine

Jonathan Bricker, Ph.D.
Faculty Member at the University of Washington and the Fred Hutchinson Cancer Research Center

Karl Fagerström, Ph.D.
Fagerström Consulting AB